These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28442583)

  • 1. Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3K
    Allen RA; Brookings DC; Powell MJ; Delgado J; Shuttleworth LK; Merriman M; Fahy IJ; Tewari R; Silva JP; Healy LJ; Davies GCG; Twomey B; Cutler RM; Kotian A; Crosby A; McCluskey G; Watt GF; Payne A
    J Pharmacol Exp Ther; 2017 Jun; 361(3):429-440. PubMed ID: 28442583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases.
    Chen S; Paveley R; Kraal L; Sritharan L; Stevens E; Dedi N; Shock A; Shaw S; Juarez M; Yeremenko N; Baeten D; Payne A
    J Autoimmun; 2020 Jul; 111():102435. PubMed ID: 32360069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions.
    Nicolas JM; Chanteux H; Nicolaï J; Brouta F; Viot D; Rosseels ML; Gillent E; Bonnaillie P; Mathy FX; Long J; Helmer E
    Eur J Pharm Sci; 2020 Jan; 142():105122. PubMed ID: 31678424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3Kδ Sustains Keratinocyte Hyperproliferation and Epithelial Inflammation: Implications for a Topically Druggable Target in Psoriasis.
    Mercurio L; Morelli M; Scarponi C; Scaglione GL; Pallotta S; Albanesi C; Madonna S
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases.
    Helmer E; Watling M; Jones E; Tytgat D; Jones M; Allen R; Payne A; Koch A; Healy E
    Eur J Clin Pharmacol; 2017 May; 73(5):581-591. PubMed ID: 28160012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The phosphoinositide-3-kinase (PI3K)-delta inhibitor seletalisib impairs monocyte-derived dendritic cells maturation, APC function, and promotes their migration to CCR7 and CXCR4 ligands.
    Scopelliti F; Mercurio L; Cattani C; Dimartino V; Albanesi C; Costanzo G; Mirisola C; Madonna S; Cavani A
    J Leukoc Biol; 2022 Sep; 112(3):383-393. PubMed ID: 35199885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome.
    Nayar S; Campos J; Smith CG; Iannizzotto V; Gardner DH; Colafrancesco S; Pipi E; Kollert F; Hunter KJ; Brewer C; Buckley CD; Bowman SJ; Priori R; Valesini G; Juarez M; Fahy WA; Fisher BA; Payne A; Allen RA; Barone F
    Ann Rheum Dis; 2019 Feb; 78(2):249-260. PubMed ID: 30472652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of PI3K Signaling Associated with T Cells in Psoriasis Is Inhibited by Seletalisib, a PI3Kδ Inhibitor, and Is Required for Functional Activity.
    Yager N; Haddadeen C; Powell M; Payne A; Allen R; Healy E
    J Invest Dermatol; 2018 Jun; 138(6):1435-1439. PubMed ID: 29307594
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of AS2541019, a novel selective PI3Kδ inhibitor, on antibody production and hamster to rat xenotransplantation.
    Marui T; Fukahori H; Kawashima T; Ito M; Akamatsu M; Kaneko Y; Takahashi F; Imada S; Morokata T
    Eur J Pharmacol; 2018 May; 826():179-186. PubMed ID: 29518396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies.
    Diaz N; Juarez M; Cancrini C; Heeg M; Soler-Palacín P; Payne A; Johnston GI; Helmer E; Cain D; Mann J; Yuill D; Conti F; Di Cesare S; Ehl S; Garcia-Prat M; Maccari ME; Martín-Nalda A; Martínez-Gallo M; Moshous D; Santilli V; Semeraro M; Simonetti A; Suarez F; Cavazzana M; Kracker S
    J Immunol; 2020 Dec; 205(11):2979-2987. PubMed ID: 33115853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization and in vivo evaluation of pyrazolopyridines as a potent and selective PI3Kδ inhibitor.
    Hamajima T; Takahashi F; Kato K; Sugano Y; Yamaki S; Moritomo A; Kubo S; Nakamura K; Yamagami K; Hamakawa N; Yokoo K; Fukahori H
    Bioorg Med Chem; 2018 Aug; 26(14):3917-3924. PubMed ID: 29907471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-Dependent Suppression of Cytokine production from T cells by a Novel Phosphoinositide 3-Kinase Delta Inhibitor.
    Way EE; Trevejo-Nunez G; Kane LP; Steiner BH; Puri KD; Kolls JK; Chen K
    Sci Rep; 2016 Jul; 6():30384. PubMed ID: 27461849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Dual-Administration Microtracer Technique to Characterize the Absorption, Distribution, Metabolism, and Excretion of [
    Helmer E; Nicolas JM; Long J; Roffel AF; Jones E; Chanteux H; Diaz N; Garratt H; Bosje T
    J Clin Pharmacol; 2017 Dec; 57(12):1582-1590. PubMed ID: 28650526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential regulation of cytokine production by PI3Kdelta in human monocytes upon acute and chronic inflammatory conditions.
    Molnarfi N; Brandt KJ; Gruaz L; Dayer JM; Burger D
    Mol Immunol; 2008 Jul; 45(12):3419-27. PubMed ID: 18471882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An investigation of the anti-inflammatory effects and a potential biomarker of PI3Kδ inhibition in COPD T cells.
    Khan A; Southworth T; Worsley S; Sriskantharajah S; Amour A; Hessel EM; Singh D
    Clin Exp Pharmacol Physiol; 2017 Sep; 44(9):932-940. PubMed ID: 28508433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient targeting of phosphoinositide 3-kinase acts as a roadblock in mast cells' route to allergy.
    Collmann E; Bohnacker T; Marone R; Dawson J; Rehberg M; Stringer R; Krombach F; Burkhart C; Hirsch E; Hollingworth GJ; Thomas M; Wymann MP
    J Allergy Clin Immunol; 2013 Oct; 132(4):959-68. PubMed ID: 23683463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitor.
    Cai Y; Yu J; Ren P; He J; Wu Z; Xiao K; Jia H; Wang J; Sai Y; Dai G; Li X; Su W; Ngo K; Castro G; Acton PD; Fung-Leung WP; Edwards JP; Venable J; Rao TS
    Pharmacol Res Perspect; 2020 Feb; 8(1):e00559. PubMed ID: 31956418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
    Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES
    J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INCB040093 Is a Novel PI3K
    Shin N; Li YL; Mei S; Wang KH; Hall L; Katiyar K; Wang Q; Yang G; Rumberger B; Leffet L; He X; Rupar M; Bowman K; Favata M; Li J; Liu M; Li Y; Covington M; Koblish H; Soloviev M; Shuey D; Burn T; Diamond S; Fridman J; Combs A; Yao W; Yeleswaram S; Hollis G; Vaddi K; Huber R; Newton R; Scherle P
    J Pharmacol Exp Ther; 2018 Jan; 364(1):120-130. PubMed ID: 29127109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignances.
    Liu X; Wang A; Liang X; Chen C; Liu J; Zhao Z; Wu H; Deng Y; Wang L; Wang B; Wu J; Liu F; Fernandes SM; Adamia S; Stone RM; Galinsky IA; Brown JR; Griffin JD; Zhang S; Loh T; Zhang X; Wang W; Weisberg EL; Liu J; Liu Q
    Oncotarget; 2016 May; 7(22):32641-51. PubMed ID: 27081697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.